v3.26.1
Segment Information
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Information
16. Segment Information
We have one reportable segment which focuses on the discovery and development of cancer therapeutics. The segment derives its revenues from the Collaboration Agreement with Jazz (see Note 4, Collaboration and License Agreement).
Our CODM manages our operations on an integrated basis for the purpose of allocating resources. When evaluating our financial performance, our CODM regularly reviews total expenses and expenses by function and makes decisions using this information based on the performance of the enterprise as a whole. Our CODM primarily evaluates the performance of the enterprise based on results that have a direct impact on our available cash and cash equivalents and accordingly places less significance on non-cash expenses such as stock-based compensation and depreciation expenses in determining how to allocate resources.
Segment assets regularly reviewed by our CODM include measures of liquidity, primarily available cash and cash equivalents, and are consistent with the presentation of cash and cash equivalents reported in our consolidated balance sheets.
The following is a summary of our segment and consolidated net loss, including significant segment expenses:
Year Ended
December 31,
20252024
(in thousands)
Collaboration revenue$— $1,885 
Less:
Clinical development19,187 16,361 
Research and discovery12,660 14,389 
General and administrative support12,428 14,330 
Manufacturing8,523 19,759 
Other segment expenses(a)
7,879 10,640 
Interest income3,108 6,673 
Interest expense(5,274)(4,656)
Loss on extinguishment of debt— (553)
Other income, net2,021 1,615 
Segment and consolidated net loss$(60,822)$(70,515)
(a) Other segment expenses includes non-cash expenses for stock-based compensation and depreciation expenses.